Impact of Two Psoriatic Arthritis Studies on Patient Care
NOVEMBER 12, 2016
At the ACR/ARHP annual meeting in Washington, DC, Philip Mease, MD, Swedish Medical Center, University of Washington, discussed the highlights from two psoriatic arthritis studies, OPAL Broaden and OPAL Beyond. Mease explained that the primary endpoints were met, providing positive news for patients suffering from this condition. "This is very important for our patients because we know that although treatment with anti-TNF medicines can be very effective, there are some patients that either have side effects or with time lose response. So, this offers us an important new treatment option, if approved, with the added benefit that it can be taken orally, and I think many patients that we treat will be very excited about this new addition for treatment."